Reduction in the Risk of Peripheral Neuropathy and Lower Decrease in Kidney Function with Metformin, Linagliptin or Their Fixed-Dose Combination Compared to Placebo in Prediabetes: A Randomized Controlled Trial.

Rafael Gabriel,Nisa Boukichou-Abdelkader,Aleksandra Gilis-Januszewska,Konstantinos Makrilakis, Ricardo Gómez-Huelgas,Zdravko Kamenov,Bernhard Paulweber,Ilhan Satman,Predrag Djordjevic,Abdullah Alkandari,Asimina Mitrakou,Nebojsa Lalic,Jesús Egido,Sebastián Más-Fontao, Jean Henri Calvet,José Carlos Pastor,Jaana Lindström,Marcus Lind,Tania Acosta,Luis Silva,Jaakko Tuomilehto, On Behalf Of The E-Predice Consortium

Journal of clinical medicine（2023）

引用 1|浏览31

暂无评分

摘要

in people with prediabetes, a 1 year treatment with metformin and linagliptin, combined or in monotherapy, was associated with a lower risk of SFPN, and with a lower decrease in eGFR, than treatment with placebo.

查看译文

关键词

antidiabetic drugs,glomerular filtration,lifestyle intervention,peripheral neuropathy risk,prediabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要